PCM
VYGR icon

Prelude Capital Management’s Voyager Therapeutics VYGR Stock Holding History

Prelude Capital Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.9K Buy
17,112
+1,400
+9% +$5.31K ﹤0.01% 1162
2026
Q1 		$60.6K Buy
+15,712
New +$61.9K ﹤0.01% 1109
2025
Q2 		– Sell
-25,817
Closed -$87.3K – 1393
2025
Q1 		$87.3K Buy
25,817
+8,017
+45% +$37.5K 0.01% 1056
2024
Q4 		$101K Sell
17,800
-2,800
-14% -$18.1K 0.01% 1094
2024
Q3 		$121K Buy
+20,600
New +$150K 0.01% 1140
2023
Q4 		– Sell
-11,715
Closed -$90.8K – 1373
2023
Q3 		$90.8K Buy
+11,715
New +$107K 0.01% 1002
2020
Q1 		– Sell
-147
Closed -$2K – 2085
2019
Q4 		$2K Buy
147
+39
+36% +$567 ﹤0.01% 1836
2019
Q3 		$2K Sell
108
-11
-9% -$231 ﹤0.01% 1623
2019
Q2 		$3K Buy
119
+44
+59% +$1.01K ﹤0.01% 1557
2019
Q1 		$1K Sell
75
-82
-52% -$1.07K ﹤0.01% 1710
2018
Q4 		$1K Buy
157
+116
+283% +$1.49K ﹤0.01% 1722
2018
Q3 		$1K Buy
+41
New +$787 ﹤0.01% 1687
2018
Q2 		– Sell
-500
Closed -$9K – 1967
2018
Q1 		$9K Buy
+500
New +$10.8K ﹤0.01% 1367
2016
Q3 		– Sell
-2,143
Closed -$24K – 1840
2016
Q2 		$24K Buy
+2,143
New +$26.2K ﹤0.01% 1223

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Prelude Capital Management's VYGR Position: Q2 2026 in Review

Prelude Capital Management increased its Voyager Therapeutics (VYGR) stake by 8.9% in Q2 2026, buying an estimated $5.31K and bringing the position to 17,112 shares worth $59.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1162.

Prelude Capital Management first reported a position in VYGR in Q2 2016 and has held it in 14 quarters since. The position peaked at $121K in Q3 2024. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Prelude Capital Management held 17,112 shares of Voyager Therapeutics worth $59.9K as of Q2 2026.
  • Prelude Capital Management bought 1,400 Voyager Therapeutics shares in Q2 2026, an estimated $5.31K.
  • Voyager Therapeutics made up ﹤0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1162 holding.
  • Prelude Capital Management first reported a position in Voyager Therapeutics in Q2 2016 and has held it in 14 quarters since.
  • Prelude Capital Management's Voyager Therapeutics position peaked at $121K in Q3 2024.
  • 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.